1) admixing or binding a biologically-active factor selected from the group consisting of TNF-α and lymphotoxin and a target molecule with a colloidal metal to form a composition; and

2) administering the composition to the human or animal.

10. (Twice Amended) The method of Claim 9, wherein the biologically-active factor is tumor necrosis factor ("TNFα").

15. (Thrice Amended) A method of treating a human or animal with a cancer or immune disease comprising administering to the human or animal with the cancer or immune disease a therapeutically effective amount of a composition capable of targeting a particular tissue comprising a biologically-active factor selected from the group consisting of TNF-α and lympotoxin and a target molecule admixed with or bound to a colloidal metal.

16. (Twice Amended) The method of Claim 15, wherein the biologically-active factor is tumor necrosis factor ("TNFα").

19. (Twice Amended) A method for the delivery of more than one biologically-active factor comprising administering to a human or animal a composition comprising more than one biologically-active factor selected from the group consisting of TNF-α and lymphotoxin and a target molecule admixed with or bound to a colloidal metal.

20. (Twice Amended) The method of Claim 19 wherein the biologically active factor is tumor necrosis factor ("TNFα").

21. (Twice Amended) A method for the targeted delivery of one or more biologically-active factors, comprising administering to a human or animal a composition comprising two or more biologically-active factors selected from the group consisting of TNF-α and lymphotoxin admixed with or bound to colloidal metal wherein at least one of the biologically-active factors is a target molecule

E5 cont

capable of binding a receptor on a cell membrane and wherein at least one of the biologically-active factors is released from the composition *in vivo*.

22. (Twice Amended) The method of Claim 21 wherein the biologically-active factor is tumor necrosis factor ("TNFα").

E6

24. (Twice Amended) A method of treating a human or animal with cancer or an immune disease comprising administering to the human or animal a composition comprising two or more biologically-active factor selected from the group consisting of TNF-α and lymphotoxin admixed with or bound to a colloidal metal, wherein at least one of the biologically-active factors is a target molecule capable of binding a receptor on a cell membrane.

25. (Twice Amended) The method of Claim 24 wherein the biologically-active factor is tumor necrosis factor ("TNFα").

E7

30. (Amended) The method of Claim 21, wherein the composition further comprises additional biologically-active factors admixed with or bound to the colloidal metal.

20

33. (Amended) A method of treating a human or animal with a cancer comprising administering to the human or animal with the cancer a therapeutically effective amount of a composition comprising a biologically-active factor selected from the group consisting of TNF-α and lymphotoxin admixed with or bound to a colloidal metal.

E8

21

34. (Amended) A method of treating a human or animal with a cancer or immune disease comprising administering to the human or animal with the cancer or immune disease a therapeutically effective amount of a composition comprising a biologically-active factor which is tumor necrosis factor ("TNFα") admixed with or bound to a colloidal metal.

E